Best Biotech Stocks To Own Right Now

After four weeks without a single IPO, the US IPO market is back from its annual August pause. Four deals are on the IPO calendar to raise $690 million in the week ahead, including:

The first energy IPO in over a year, an MLP with a 7.5% annualized yield
A VC-backed tech company (2016’s tech IPO class is up over +100% on average)
A large Bermuda bank and wealth manager with a 5.4% annualized yield
A small but fast-growing regional bank in Tennessee
The week could also see offerings from a small biotech and SPAC

Renaissance Capital’s IPO Calendar – Week of 9/12/2016 Issuer
Business Symbol
Exchange Deal Size
$mil Price Range
Shares Filed Lead Managers The Bank of N.T. Butterfield & Son
Hamilton, Bermuda NTB
NYSE $250 $22 – $25
10,638,298 Goldman Sachs
Citi Bank and wealth manager operating in Bermuda and the Cayman Islands. Noble Midstream Partners LP
Houston, TX NBLX
NYSE $250 $19 – $21
12,500,000 Barclays
Baird MLP formed by Noble to own oil and gas gathering assets in Colorado’s DJ basin. FB Financial
Nashville, TN FBK
NYSE $100 $16 – $18
5,882,352 J.P. Morgan
UBS Investment Bank Tennessee bank with 45 branches and $2.9 billion in assets. Everbridge
Burlington, MA EVBG
Nasdaq $90 $11 – $13
7,500,000 Credit Suisse
BofA Merrill Lynch Provides mass messaging and critical communications services to enterprises. M I Acquisitions
New York, NY MACQU
Nasdaq $50 $10 – $10
5,000,000 Chardan Capital Markets Blank check company formed to acquire a technology, media or telecom company. AzurRX Biopharma
Brooklyn, NY AZRX
Nasdaq $12 $6 – $8
1,700,000 WallachBeth Capital
Network 1 Financial Developing non-systemic biologics for gastrointestinal disorders. Click to enlarge

2016’s first energy IPO hopes a 7.5% yield will get it the royal treatment
Noble Midstream Partners LP (NYSE:NBLX) is the first energy company to attempt an IPO since its last attempt in November 2015. The last US oil and gas IPO was PennTex Midstream Partners LP ((NASDAQ:PTXP); -12%). Noble will test investors’ hunger for yield (7.5% at the midpoint) and aversion to energy growth stories.

Best Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.

    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

  • [By Keith Speights]

    Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren’t high on the list when it came to dividends. Over the past few years, though, Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD) have risen in prominence as attractive alternatives for dividend-seeking investors.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

  • [By Tom Gentile]

    After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.

Best Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

Best Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stocks 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

Best Biotech Stocks To Own Right Now: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Ben Levisohn]

    Medivation (MDVN) has soared 20% to $80.41 after agreeing to be purchased for $14 billion, or $81.50 a share, by Pfizer (PFE). Pfizer has declined 0.7% to $34.75.

  • [By Ben Levisohn]

    Last night, Bloomberg reported that Sanofi (SNY) had made a bid for Medivation (MDVN) but had been rebuffed, while noting that other companies–perhaps Gilead Sciences (GILD), Amgen (AMGN) or AstraZeneca (AZN)?–were also on the prowl. SunTrust Robinson Humphrey’s Peter Lawson explains why Medivation might be biotech’s most wanted:

Best Biotech Stocks To Own Right Now: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Best Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Leave a Reply

Your email address will not be published. Required fields are marked *